Neuroleptic dose reduction in older psychotic patients

Schizophrenia Research

Volumn 27, Issue 2-3, 1997, Pages 241-248

  Harris, M Jackuelyn ^a   Heaton, Robert K ^a   Schalz, Alice ^a   Bailey, Anne ^a   Patterson, Thomas L ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Dose reduction; Neuroleptic; Psychosis

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGED; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSIS;

AGE FACTORS; AGE OF ONSET; AGED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0030827489     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(97)00083-2     Document Type: Conference Paper

References (40)

1. American Psychiatric Association, 1987. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. American Psychiatric Press, Washington, DC.
2. American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Association, Washington, DC.
3. Andrews, P., Hall, J.N., Snaith, R.P., 1976. A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients. Br. J. Psychiatry 128, 451-455.
4. Angst, J., 1988. European long-term followup studies of schizophrenia. Schizophr. Bull. 14, 501-513.
5. Bleuler, M., 1978. The Schizophrenic Disorders: Long-term Patient and Family Studies. Translated by S.M. Clemens. Yale University Press, New Haven, Connecticut.
6. Brandt, J., 1991. The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clin. Neuropsychol. 5, 125-142.
7. Brown, W.A., Laughren, T., 1981. Low serum prolactin and early relapse following neuroleptic withdrawal. Am. J. Psychiatry 138, 237-239.
8. Ciompi, L., 1980. Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophr. Bull. 6, 606-618.
9. Ciompi, L., 1987. Review of follow-up studies on long-term evolution and aging in schizophrenia. In: Miller, N.E., Cohen, G.D. (Eds.), Schizophrenia and Aging, Guilford Press, New York.
10. Cohen, C.I., 1990. Outcome of schizophrenia into later life: an overview. Gerontologist 30, 790-797.
11. Davis, J.M., 1975. Overview: Maintenance Therapy in Psychiatry: I. Schizophrenia. Am. J. Psychiatry 132, 1237-1245.
12. Folstein, M.F., Folstein, S.E., McHugh, P.R., 1975. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189-198.
13. Gilbert, P.L., Harris, M.J., McAdams, L.A. et al., 1995. Neuroleptic withdrawal in schizophrenic patients. Arch. Gen. Psychiatry 52, 173-188.
14. Glazer, W.M., Bowers, M.B., Charney, D.S. et al., 1989. The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia. Biol. Psychiatry 26, 224-233.
15. Golden, C.J., 1978. Stroop Color and Word Test. Stoelting Company, Chicago.
16. Green, A.I. et al., 1992. Neuroleptic dose reduction studies: Clinical and neuroendocrine effects. American College of Neuropsychopharmacology. December, 39 (Abstract).
17. Harding, C.M., Brooks, G.W., Ashikaga, T. et al., 1987a. The Vermont longitudinal study: II. Long-term outcome of subjects who once met the criteria for DSM-III schizophrenia. Am. J. Psychiatry 144, 727-735.
18. Harding, C.M., Brooks, G.W., Ashikaga, T. et al., 1987b. The Vermont longitudinal study of persons with severe mental illness, I. Methodology, study sample and overall status 32 years later. Am. J. Psychiatry 144, 718-726.
19. Heaton, R., Paulsen, J., McAdams, L.A. et al., 1994. Neuropsychological deficits in schizophrenia: relationship to age, chronicity and dementia. Arch. Gen. Psychiatry 51, 469-476.
20. Huber, G., Gross, G., Schuttler, R. et al., 1980. Longitudinal studies of schizophrenia patients. Schizophr. Bull. 6 (4), 592-605.
21. Inderbitzin, L.B., Lewine, R.R., Scheller-Gilkey, G. et al., 1994. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. Am. J. Psychiatry 151, 1753-1759.
22. Jeste, D.V., Caligiuri, M.P., Paulsen, J.S. et al., 1995. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 patients. Arch. Gen. Psychiatry 52, 756-765.
23. Kane, J.M., 1989. Schizophrenia: Somatic Treatment. In: Kaplan, H.I., Sadock, B.J. (Eds.), Comprehensive Textbook of Psychiatry. Williams & Wilkins, New York.
24. Kaplan, R.M., Anderson, J.P., Wu, A.W. et al., 1989. The Quality of Well-Being scale. Applications in AIDS, cystic fibrosis, and arthritis. Med. Care 27, S27-S43.
25. Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261-276.
26. Lewis, R.F., Rennick, P.M., 1979. Manual for the Repeatable Cognitive-Perceptual-Motor Battery. Axon, Grosse Point Park, Michigan.
27. Lieberman, J.A., Kane, J.M., Sarantakos, S. et al., 1987. Prediction of relapse in schizophrenia. Arch. Gen. Psychiatry 44, 597-603.
28. National Institute of Mental Health, 1976. Abnormal Involuntary Movement Scale. In: Guy, W. (Ed.), ECDEU Assessment Manual for Psychopharmacology-Revised. US Department of Health, Education, and Welfare Pub. No. (ADM)76-338, Rockville, Maryland, pp. 534-537.
29. Orzak, M.H., Kornetsky, C., Freeman, H., 1967. The effects of daily administration of carphenazine on attention in the schizophrenic patient. Psychopharmacologia 11, 31-38.
30. Patterson, T.L., Kaplan, R.M., Grant, I. et al., 1996. Quality of well-being in late-life psychosis. Psychiatry Res. 63, 169-181.
31. Prudo, R., Blum, H.M., 1987. Five-year outcome and prognosis in schizophrenia: a report from the London Field Research Centre of the International Pilot Study of Schizophrenia. Br. J. Psychiatry 150, 345-354.
32. Rassidakis, N.C., Kondakis, X., Papanastassiou, A. et al., 1970. Withdrawal of antipsychotic drugs from chronic psychiatric patients. Bull. Menninger Clin. 34, 216-222.
33. Ruskin, P.E., Nyman, G., 1991. Discontinuation of neuroleptic medication in older, outpatient schizophrenics: a placebo-controlled, double-blind trial. J. Nerv. Ment. Dis. 179, 212-214.
34. Seidman, L.J., Pepple, J.R., Faraone, S.V. et al., 1993. Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction. Biol. Psychiatry 33, 575-584.
35. Simpson, G.M., Angus, J.W., 1970. A rating scale for extrapyramidal side effects. Acta. Psychiatr. Scand. 212, 11-19.
36. Smith, R.C., 1994. Lower-dose therapy with traditional neuroleptics in chronically hospitalized schizophrenic patients. Arch. Gen. Psychiatry 51, 427-429.
37. Spohn, H., Lacoursiere, R., Thompson, K. et al., 1977. Phenothiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenia. Arch. Gen. Psychiatry 34, 633-644.
38. Tsuang, M., Woolson, R., Fleming, J., 1979. Long-term outcome of major psychosis: I. Schizophrenia and affective disorders compared with psychiatrically symptom free surgical conditions. Arch. Gen. Psychiatry 36, 1295-1301.
39. Wechsler, D., 1981. WAIS-R Manual. Wechsler Adult Intelligence Scale-Revised. The Psychological Corporation, New York.
40. Zander, K.J., Fischer, B., Zimmer, R. et al., 1981. Long-term neuroleptic treatment of chronic schizophrenic patients: Clinical and biochemical effects of withdrawal. Psychopharmacology 73, 43-47.